Notably, the dual S1P1+5 modulator ozanimod, which is currently in clinical trials for multiple sclerosis, inflammatory bowel disease and COVID-19, is metabolized to two active structures, which produce most of the clinical effects of the drug [26]. Here, S1PR1 is linked to multiple sclerosis.